menu
    • menu

    Company profile for LimmaTech Biologics

    NEW Drugs in Dev: 11
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LimmaTech BiologicsSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Grabenstrasse 3 8952 Schlieren
    Telephone
    Telephone
    +41 44 733 8585
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://lmtbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/limmatech-biologics-ag/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lilly Announces 3 Acquisitions to Build Infectious Disease Portfo
    Lilly Announces 3 Acquisitions to Build Infectious Disease Portfo

    26 May 2026

    // PRESS RELEASE

    https://investor.lilly.com/news-releases/news-release-details/lilly-announces-three-acquisitions-build-infectious-disease

    PRESS RELEASE
    26 May 2026
    Share Share
    Valneva, LimmaTech Start Ph 2 Shigella Vaccine in Infants
    Valneva, LimmaTech Start Ph 2 Shigella Vaccine in Infants

    09 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/09/3058098/0/en/Valneva-and-LimmaTech-Announce-First-Vaccination-in-Phase-2-Infant-Study-of-Tetravalent-Shigella-Vaccine-Candidate-S4V2.html

    GLOBENEWSWIRE
    09 Apr 2025
    Share Share
    LimmaTech Starts Ph 1 Trial For Staphylococcus Aureus Vaccine
    LimmaTech Starts Ph 1 Trial For Staphylococcus Aureus Vaccine

    17 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250217309427/en

    BUSINESSWIRE
    17 Feb 2025
    Share Share
    LimmaTech Awarded FDA Fast Track for Staph aureus Vaccine
    LimmaTech Awarded FDA Fast Track for Staph aureus Vaccine

    19 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241219504299/en

    BUSINESSWIRE
    19 Dec 2024
    Share Share
    Valneva & LimmaTech Begin Phase 2b Shigella Vaccine Study
    Valneva & LimmaTech Begin Phase 2b Shigella Vaccine Study

    13 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/13/2980515/0/en/Valneva-and-LimmaTech-Announce-First-Vaccination-in-Phase-2b-Human-Challenge-Study-of-Tetravalent-Shigella-Vaccine-Candidate-S4V2.html

    GLOBENEWSWIRE
    13 Nov 2024
    Share Share
    Valneva And LimmaTech Awarded FDA Fast Track For Tetravalent Shigella
    Valneva And LimmaTech Awarded FDA Fast Track For Tetravalent Shigella

    16 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/16/2964323/0/en/Valneva-and-LimmaTech-Awarded-FDA-Fast-Track-Designation-for-Tetravalent-Shigella-Vaccine-Candidate-S4V.html

    GLOBENEWSWIRE
    16 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search